Latest news with #painrelief
Yahoo
14 hours ago
- Health
- Yahoo
Tylenol doesn't work the way we thought it does
When you buy through links on our articles, Future and its syndication partners may earn a commission. Acetaminophen is widely used to relieve pain, but exactly how it works has long been a mystery. Now, a new study suggests that a key byproduct of acetaminophen may block pain signals at the nerves — before they can reach the brain. Acetaminophen, also called paracetamol or Tylenol, is broken down by the liver into a compound called 4-aminophenol, which travels through the bloodstream to different organs. There, an enzyme links it with a fatty acid to produce AM404. Previous research found that AM404 can act in the central nervous system — the brain and spinal cord. But the new study, published June 4 in the journal PNAS, reveals that AM404 also affects the peripheral nervous system, where pain signals originate. "These results fundamentally change our understanding of paracetamol's mode of action," study co-authors Alexander Binshtok, a professor in pain research, and Avi Priel, a professor of pharmacy, both at the Hebrew University of Jerusalem, told Live Science in an email. Nial Wheate, a professor of pharmaceutical chemistry at Macquarie University in Australia, who wasn't involved in the study, agreed. "Even though we have been using paracetamol for the management of pain for more than 130 years, we still don't fully understand how the drug works," Wheate told Live Science. One widely held theory was that acetaminophen stopped the body from making. prostaglandins, which can trigger pain and inflammation, he said."If the results of this study are confirmed, then it significantly changes our understanding of the drug." However, the new study was in rats, so the findings may not apply in humans, he added. To test the effects of AM404, the scientists applied the compound to sensory neurons taken from newborn rats. They found that it blocks sodium channels — proteins that normally allow charged sodium particles to pass in and out of cells, which are essential for generating and transmitting pain signals. By blocking these channels, AM404 keeps the neurons from sending pain messages to the brain. Other byproducts of acetaminophen had no such effect. The researchers also injected AM404 into the paws of rats and tested their responses to painful stimuli. The treated paws became less sensitive to heat and pressure, with the strongest effect appearing about an hour after the injection. Importantly, the pain relief was limited to the site of the injection, leaving the other paw unaffected. While the findings may not change how acetaminophen is currently used to treat pain, they could influence the development of next-generation painkillers that are potentially safer, Wheate said. Acetaminophen overdoses can damage the liver and are responsible for 56,000 emergency visits a year in the U.S. RELATED STORIES —FDA approves 1st new class of opioid-free painkillers in over 20 years —Ozempic in a pill? New oral drug may work as well as Ozempic-style injectables —Acne vaccine: Experimental shot for common skin condition reaches clinical trials. Here's what you need to know. "Whole families of new drugs could be designed based around blocking sodium channels. These new drugs could be both more effective and safer than not just paracetamol, but other painkillers like ibuprofen or the opioids," Wheate said. Looking ahead, Binshtok and Priel hope to design improved versions of AM404 that are more chemically stable and optimized to work in the peripheral nervous system, they added. They also plan to test whether these compounds can help with chronic or nerve-related pain, where standard treatments often fall short. Another important next step is to assess the safety and therapeutic potential of AM404 in greater detail. This involves understanding how it is broken down and distributed in the body and whether it might affect any other organs.
Yahoo
a day ago
- Health
- Yahoo
Theranica to Present Three Real-World Evidence Studies at AHS Scientific Meeting Highlighting the Impact of the Nerivio® REN Wearable on Migraine Treatment
New studies confirm the clear benefit of early acute treatment, the consistent effectiveness of REN over years, and its clinical benefits in migraine both with and without aura BRIDGEWATER, N.J. and NETANYA, Israel, June 19, 2025 (GLOBE NEWSWIRE) -- Theranica, a pioneer in drug-free neuromodulation treatments for idiopathic pain conditions, today announced the presentation of three new real-world studies at the 2025 American Headache Society (AHS) 67th Annual Scientific Meeting, held in Minneapolis, Minnesota. The posters highlight the safety, efficacy, and versatility of the company's prescribed, FDA-cleared Nerivio® REN wearable, the first-and-only remote electrical neuromodulation (REN) therapy indicated for both acute and preventive treatment of migraine in people aged 8 and older. Among the highlights is a long-term study demonstrating that the REN wearable maintains consistent efficacy for migraine treatment over three years of use, with no signs of tachyphylaxis or 'treatment fatigue.' Throughout the study period, patients experienced consistent Pain Relief, Functional Recovery (see Figure), and freedom from migraine-associated symptoms such as photophobia, phonophobia, and nausea/vomiting.'These findings speak to a critical need in migraine treatment: durability with continued use,' said Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, Assistant Director, Headache Medicine Fellowship Program, Jefferson Headache Center and Professor, Department of Neurology, Thomas Jefferson University. 'Migraine disease is complex and non-curable, yet too often patients struggle to find safe, well-tolerated treatments with sustained efficacy over time, something that is necessary to mitigate chronification and maintain quality of life. Seeing ongoing patient adherence with consistent results over a three-year span, without the risk of treatment fatigue, rebound symptoms, or gradually degraded response confirms the REN wearable as a sustainable, non-drug option for the long-term management of a complex condition such as migraine.' Another poster compares REN's impact in treating migraine with and without aura (MWA and MWoA) in nearly 32,000 patients. Despite having more severe baseline symptoms, patients with aura experienced treatment outcomes that were comparable, and in some measures slightly better than in patients without aura. Pain Relief, Functional Recovery, and freedom from migraine-associated symptoms were evident in both groups, reinforcing the REN wearable's reliable performance across these two major migraine subtypes. 'These studies represent some of the most comprehensive real-world analyses to date on the use of REN in migraine treatment. Together, they demonstrate that REN is not only effective when used early for acute treatment—but also durable over time and beneficial across different migraine subtypes,' said Alit Stark-Inbar, Ph.D., VP Medical Information and Research at Theranica. 'Presenting these data at AHS is an excellent vehicle to share clinically meaningful insights with the professional headache community, and to further support physicians in making evidenced-based decisions when taking care of their patients, being well educated about their treatment options'. These recent clinical data reinforce the REN wearable's unique position as a non-drug treatment of migraine, clinically proven to work both acutely and preventively. For patients facing intolerability or lack of efficacy with medications, or seeking non-pharmacological alternatives, Nerivio delivers safe, effective, and non-disruptive relief, without compromising outcomes. As an active participant in this year's AHS 67th Annual Scientific Meeting, held at the Minneapolis Convention Center from June 18 to 22, Theranica reaffirms its commitment to scientific exchange, clinical innovation, and engagement with the broader headache community. AHS remains a cornerstone in advancing migraine intervention and education, and Theranica is proud to contribute meaningful data that help shape the future of the field. Attendees are invited to visit Theranica at booth #501 to learn more. Information can also be found at About NerivioThe Nerivio® REN wearable is an acute and preventive (dual-use) prescription migraine treatment that works without drugs, needles, or invasive procedures. FDA-cleared for patients 8 and above, it uses gentle electrical pulses on the arm to activate the brain's natural pain regulation system, relieving migraine symptoms during an attack, and reducing the frequency and burden of future episodes when used preventively. Controlled by a smartphone app, the Nerivio REN wearable offers a safe, effective, and easy-to-use way to manage migraine—without the risk of systemic side effects or drug interactions. About TheranicaTheranica is a neuromodulation therapeutics company pioneering drug-free treatments for idiopathic pain conditions. Its FDA-cleared flagship product, Nerivio®, is the first-and-only prescribed REN wearable for both acute and preventive migraine care. Used in more than one million treatments across the U.S., Nerivio provides a much-needed option for migraine patient populations with unique qualities, including children, veterans, individuals managing comorbidities, and women of childbearing age. Dedicated to modernizing pain management without drugs or needles, Theranica continues to develop cutting-edge neuromodulation therapies that reshape the way pain is treated. Theranica Contact: Ronen Jashekronenj@ Media Contact:Grey Matter Marketingmedia@ A photo accompanying this announcement is available at: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
2 days ago
- Health
- Fox News
NSAIDs vs. acetaminophen: What you need to know before your next headache
Most households have a stash of painkillers tucked away for surprise headaches or stubborn cramps. But some may not realize that all painkillers are not created equal, and they don't all treat the same kind of pain. Over-the-counter (OTC) pain relievers fall into two main categories, according to MedLine Plus. The first is NSAIDs (non-steroidal anti-inflammatory drugs) like ibuprofen and naproxen. "These reduce both pain and inflammation, but can irritate the stomach if not taken with food," Dr. Jessica Oswald, MD, MPH, an anesthesiologist and pain management specialist at UC San Diego Health, told Fox News Digital. The other medication, acetaminophen, also helps with pain and fever, but does not reduce inflammation, Oswald noted. Dr. Min "Frank" Wu, a physician at AdventHealth in Littleton, Colorado, elaborated on how these drugs work differently in the body. NSAIDs are effective in treating fever and pain relief, the doctor told Fox News Digital. These medications can alleviate a variety of symptoms related to arthritis, infection, back injury, headaches and muscle strain, along with other acute and chronic conditions that cause pain and inflammation, he said. "NSAIDs work by inhibiting cyclooxygenase enzymes (COX-1 and COX-2) throughout the body," he noted, which means they inhibit the production of "biological mediators" that cause inflammation and blood clotting. Acetaminophen, on the other hand, works by "inhibiting COX enzymes and modulating the endocannabinoid system in the central nervous system (brain and spinal cord) to exert its effects," Wu said. As a pain reliever, acetaminophen is effective for migraines, according to the doctor. "In combination, acetaminophen/caffeine is recommended as a first-line agent by many European agencies," he noted. Acetaminophen's effectiveness for arthritic pain, however, is small and not clinically important, according to Wu. "It has not been shown to be effective for low back pain or radicular (nerve pain) in general," he added. Wu pointed out that acetaminophen appears to boost the pain-relief properties of other medications. "The combination of acetaminophen and NSAIDs has been shown to be more effective than either medication alone," Wu said. Oswald also spoke about this method, which she calls a "multimodal" approach. "In many cases, combining different types of pain relievers can be more effective than using just one," she told Fox News Digital. For example, an NSAID like ibuprofen along with acetaminophen and a topical cream "can work together to relieve pain more effectively," Oswald said. Research has shown that NSAIDs have multiple adverse effects and should be used with caution, both doctors pointed out. "They have been shown to cause gastrointestinal issues, and in severe cases can cause ulcers and bleeding," Wu noted. These side effects appear to be dependent on the size of the dose, the doctor added. "In many cases, combining different types of pain relievers can be more effective than using just one." There is evidence of increased gastric effects, kidney impairment and heart disease at higher doses. The U.S. Food and Drug Administration (FDA) has also issued warnings about cardiovascular risk. At high enough doses, it can (less commonly) cause liver damage, which can potentially be fatal, according to Wu. Oswald recommended that people with certain health conditions — such as kidney problems, heart issues or stomach ulcers — should talk to a doctor before using NSAIDs. Acetaminophen has been linked to a potential risk of liver injury and allergic reactions, according to the FDA. Rare but serious skin reactions have also been reported. "Acetaminophen is generally safer for most people, as long as they stay under 3,000 milligrams per day," Oswald added. After weighing the benefits and risks, the doctor said that people should "absolutely" keep both types of OTC medications on hand at home. "Having a few different options allows you to manage pain more effectively by targeting it in different ways," she said. For more Health articles, visit Ultimately, if pain doesn't improve or keeps coming back, it's best to consult a healthcare professional who can assess the cause and discuss other treatment options, including prescription medications.
Yahoo
4 days ago
- Business
- Yahoo
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized placebo-controlled Phase 3 studies If approved by FDA, TNX-102 SL would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years CHATHAM, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) presented data in a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, held June 11-14, 2025, in Barcelona, Spain. A copy of the Company's poster, titled 'Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Targets Non-restorative Sleep and Provides Sustained Pain Reduction' is available under the Scientific Presentations tab of the Tonix website at TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic designed for daily bedtime dosing with an FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025. 'Fibromyalgia is a complex and invisible chronic pain condition which drives many patients to be prescribed chronic opioids which are associated with addiction and overdose,' said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. 'To address the chronic symptoms of fibromyalgia, potential therapeutic options must provide durable benefits. TNX-102 SL has shown statistically significant, durable activity (14 weeks) in reducing fibromyalgia pain in two Phase 3 studies. Designed to target the sleep disturbance of fibromyalgia, TNX-102 SL harnesses the therapeutic activity of cyclobenzaprine in part by reducing in the level of the active metabolite norcyclobenzaprine relative to oral cyclobenzaprine. Norcyclobenzaprine is believed to interfere with the durability of oral cyclobenzaprine's treatment effect in off-label chronic dosing regimens and in a failed double-blind randomized placebo-controlled trial.1 TNX-102 SL now has the potential to be the first new treatment option for fibromyalgia patients in 15 years.' TNX-102 SL is designed for transmucosal absorption to bypass first-pass hepatic metabolism. The poster presentation shows the day 20 steady state blood levels from a study of nightly TNX-102 SL dosing in which the peak level of cyclobenzaprine exceeds the level of the active metabolite norcyclobenzaprine during sleep time. In contrast, with nightly oral cyclobenzaprine dosing, pharmacokinetic simulations show that norcyclobenzaprine accumulates to higher levels, and the cyclobenzaprine peak level does not exceed the norcyclobenzaprine level during sleep time. The poster includes data from the RESILIENT Phase 3 study evaluating the efficacy and safety of TNX-102 SL with a primary endpoint of reducing daily pain numeric rating scale scores after 14 weeks of treatment. TNX-102 SL significantly reduced pain and improved clinical outcomes in fibromyalgia patients while demonstrating a favorable tolerability profile. TNX-102 SL employs a novel mechanism targeting the sleep disturbance in fibromyalgia by acting as a potent antagonist at four post-synaptic receptors, each of which is known to regulate sleep. About Fibromyalgia Fibromyalgia is a common chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system, called central sensitization. Brain imaging studies have localized the functional disorder to the brain's insula and anterior cingulate cortex. Fibromyalgia afflicts more than 10 million adults in the U.S., the majority of whom are women. Symptoms of fibromyalgia include chronic widespread pain, non-restorative sleep, fatigue, and brain fog (or cognitive dysfunction). Other associated symptoms include mood disturbances, including depression, anxiety, headaches and abdominal pain or cramps. Individuals suffering from fibromyalgia often struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products. Fibromyalgia is now recognized as the prototypic nociplastic syndrome. Nociplastic pain is the third primary type of pain in addition to nociceptive pain and neuropathic pain. Many patients present with pain syndromes that are mixtures of the three primary types of pain. Nociplastic syndromes are associated with central and peripheral sensitization. Fibromyalgia can occur without any identifiable precipitating event. However, many fibromyalgia cases follow one or more precipitating event(s) including: post-operative pain, acute or chronic nociceptive or neuropathic pain states; recovery from an infectious illness; a cancer diagnosis or cancer treatment; a metabolic or endocrine stress; or a traumatic event. In the cases of recovery from an infectious illness, fibromyalgia is considered an Infection-Associated Chronic Condition. In addition to fibromyalgia cases associated with other conditions or stressors, the U.S. National Academies of Sciences, Engineering, and Medicine, has concluded that fibromyalgia is a diagnosable condition that can occur after recovery from COVID-19 in the context of Long COVID. About TNX-102 SL TNX-102 SL is a centrally acting, non-opioid investigational drug, designed for chronic use. The tablet is a patented sublingual formulation of cyclobenzaprine hydrochloride developed for bedtime dosing for the management of fibromyalgia. Cyclobenzaprine potently binds and acts as an antagonist at four different post-synaptic neuroreceptor subtypes: serotonergic-5-HT2A, adrenergic-α1, histaminergic-H1, and muscarinic-M1-cholinergic receptors. Together, these interactions are believed to target the non-restorative sleep characteristic of fibromyalgia identified by Professor Harvey Moldofsky in 1975. Cyclobenzaprine is not associated with risk of addiction or dependence. The TNX-102 SL tablet is based on a eutectic formulation of cyclobenzaprine HCl and mannitol that provides a stable product which dissolves rapidly and delivers cyclobenzaprine by the transmucosal route efficiently into the bloodstream. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. Patents based on TNX-102 SL's eutectic composition and its properties have issued in the U.S., E.U., Japan, China and many other jurisdictions around the world and provide market protection into 2034. The European Patent Office's Opposition Division maintained Tonix's European Patent EP 2 968 992 in unamended form after an Opposition was filed against it by a Sandoz subsidiary, Hexal AG. Hexal AG did not appeal that decision. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, while reducing the risk of daytime somnolence. Clinical pharmacokinetic studies indicated that relative to oral cyclobenzaprine, TNX-102 SL results in higher levels of exposure during the first 2 hours after dosing and in deceased levels of the long-lived active metabolite, norcyclobenzaprine in both single dose and multiple dose studies, consistent with bypassing first pass hepatic metabolism. Cyclobenzaprine is a tertiary amine tricyclic and its active metabolite norcyclobenzaprine is a secondary amine tricyclic. At steady state after 20 days of dosing TNX-102 SL, the dynamic peak level of cyclobenzaprine is higher than the background level of norcyclobenzaprine during sleep time. In contrast, after 20 days of dosing oral cyclobenzaprine, the simulated peak level of cyclobenzaprine is lower than the simulated background level of norcyclobenzaprine. Tonix Pharmaceuticals Holding Corp.* Tonix is a fully integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix's development portfolio is focused on central nervous system (CNS) disorders. Tonix's priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix's infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD's Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. 1Carette S, et al. Arthritis Rheum. 1994;37(1):32-40. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'expect,' and 'intend,' among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the 'SEC') on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contact Jessica MorrisTonix (862) 799-8599 Peter VozzoICR (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@ 245-5432 Indication and Usage Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine. Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age. Important Safety Information Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. Do not use Zembrace or Tosymra if you have: history of heart problems narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease) uncontrolled high blood pressure hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider. had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation severe liver problems taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure. are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure. an allergy to sumatriptan or any of the components of Zembrace or Tosymra Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. Zembrace and Tosymra may cause serious side effects including: changes in color or sensation in your fingers and toes sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet increased blood pressure including a sudden severe increase even if you have no history of high blood pressure medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider. serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking. hives (itchy bumps); swelling of your tongue, mouth, or throat seizures even in people who have never had seizures before The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit or call 1-888-869-7633. You are encouraged to report adverse effects of prescription drugs to the FDA. Visit or call in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Independent
10-06-2025
- Health
- The Independent
Why China is making hospitals offer women pain relief for childbirth
China has mandated that all tertiary hospitals (over 500 beds) must offer epidural anaesthesia during childbirth by the end of 2024, with plans to extend to secondary hospitals (over 100 beds) by 2027. The initiative aims to create a more "friendly childbearing environment" amid declining birth rates in China. Currently, only about 30% of pregnant women in China receive anesthesia for pain relief during childbirth, compared to over 70% in some developed countries. The World Health Organisation recommends epidurals for healthy pregnant women, and they are widely used in countries like France, the United States, and Canada. To encourage more women to have children, an increasing number of provinces in China are including childbirth anesthesia costs in medical insurance schemes, and some provinces are extending marriage and maternity leave.
